Your browser is no longer supported. Please, upgrade your browser.
GTHX G1 Therapeutics, Inc. daily Stock Chart
G1 Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.40 Insider Own10.10% Shs Outstand28.82M Perf Week12.26%
Market Cap1.17B Forward P/E- EPS next Y-3.01 Insider Trans- Shs Float20.36M Perf Month83.87%
Income-64.90M PEG- EPS next Q-0.63 Inst Own57.10% Short Float4.74% Perf Quarter107.86%
Sales- P/S- EPS this Y-181.70% Inst Trans54.15% Short Ratio4.98 Perf Half Y62.53%
Book/sh3.69 P/B10.97 EPS next Y-21.90% ROA-65.20% Target Price43.00 Perf Year-
Cash/sh3.60 P/C11.24 EPS next 5Y- ROE-105.90% 52W Range12.04 - 41.92 Perf YTD103.98%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-3.46% Beta-
Dividend %- Quick Ratio8.90 Sales past 5Y- Gross Margin- 52W Low236.13% ATR2.80
Employees44 Current Ratio8.90 Sales Q/Q- Oper. Margin- RSI (14)73.22 Volatility8.50% 9.95%
OptionableNo Debt/Eq0.00 EPS Q/Q-58.30% Profit Margin- Rel Volume3.69 Prev Close40.11
ShortableYes LT Debt/Eq0.00 EarningsFeb 21 AMC Payout- Avg Volume193.93K Price40.47
Recom1.60 SMA2027.29% SMA5053.94% SMA20089.59% Volume715,339 Change0.90%
Mar-16-18 08:10AM  New Research Coverage Highlights Amarin, Corbus Pharmaceuticals, Green Brick Partners, Immutep, Texas Capital Bancshares, and G1 THERAPEUTICS Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Mar-14-18 02:25PM  G1 CEO talks 2018 growth American City Business Journals
08:48AM  G1 Therapeutics (GTHX) in Focus: Stock Moves 8.9% Higher Zacks
Mar-12-18 04:05PM  G1 Therapeutics Announces Closing of Offering of Common Stock GlobeNewswire
Mar-07-18 09:54PM  G1 Therapeutics Announces Pricing of Offering of Common Stock GlobeNewswire +14.35%
Mar-05-18 04:18PM  G1 Therapeutics Announces Proposed Offering of Common Stock GlobeNewswire
03:30PM  G1 sees stock bump on big data readout American City Business Journals
07:40AM  Wired News FDA Granted Fast Track Designation to FibroGens Pamrevlumab for Locally Advanced Unresectable Pancreatic Cancer ACCESSWIRE
06:00AM  G1 Therapeutics Announces Positive Trilaciclib Phase 2a Topline Data Showing Robust Myelopreservation Benefits in Patients with Small Cell Lung Cancer GlobeNewswire
Mar-01-18 07:00AM  G1 Therapeutics to Present at Investor Conferences in March 2018 GlobeNewswire +5.67%
Feb-26-18 06:19PM  Edited Transcript of GTHX.O earnings conference call or presentation 21-Feb-18 9:30pm GMT Thomson Reuters StreetEvents
Feb-21-18 04:01PM  G1 Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights GlobeNewswire
Feb-14-18 07:00AM  G1 Therapeutics to Report Fourth Quarter and Full-Year 2017 Financial Results on February 21, 2018 GlobeNewswire
Jan-02-18 07:00AM  G1 Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-18-17 07:00AM  G1 Therapeutics Added to Nasdaq Biotechnology Index GlobeNewswire
Dec-06-17 04:54PM  G1 Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-28-17 07:00AM  G1 Therapeutics and AstraZeneca Enter Clinical Trial Collaboration in Non-Small Cell Lung Cancer GlobeNewswire
Nov-11-17 12:01AM  [$$] Triggering a Debt Bomb
Nov-08-17 07:30AM  G1 Therapeutics Reports Third Quarter 2017 Financial Results and Recent Operational Highlights GlobeNewswire
07:00AM  G1 Therapeutics Makes Key Executive Appointments GlobeNewswire
Nov-07-17 08:00AM  G1 Therapeutics to Present at Stifel 2017 Healthcare Conference GlobeNewswire
Nov-06-17 07:00AM  G1 Therapeutics Announces Publication in Cancer Discovery Demonstrating That CDK4/6 Inhibition Enhances the Anti-Tumor T Cell Response GlobeNewswire
Jun-09-17 10:42AM  Retail Investors: Your IPOs Are Here Benzinga
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel therapeutics for the treatment of cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/IIa clinical trials for patients with small cell lung cancer, as well as Phase II clinical trial for patients with triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase I/II clinical trial for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader that is in preclinical development stage. The company has a clinical trial collaboration agreement with AstraZeneca to evaluate AstraZeneca??s epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor Tagrisso (osimertinib) in combination with oral CDK4/6 inhibitor G1T38 for the treatment of EGFR mutation-positive non-small cell lung cancer; and a research partnership GeneCentric Therapeutics, Inc. to identify subtypes of lung cancer where the compound is likely to be efficacious. G1 Therapeutics, Inc. was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.